StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — HSBC Securities

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

byHSBC SecuritiesHorizon: NA (inferred 1 year)7 Oct 2026via Zee Business (Live)

Entry₹1,797.1Inferred
Target₹2,100
Total upside +16.85%
Stop lossNot given
CMP₹1,759.83h ago
Active-2.08%+19.33%upside left 12 mo left
Follow HSBC Securities for new calls(100% target hit, 14 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 14 other Long-term calls on SUNPHARMASee 105 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Oct, 7:54 pm IST
13 supporting4 neutral4 opposing
Supports the BUY call (13)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·7 Oct · yesterday

Sun Pharma to acquire Innovcare Lifesciences for ₹271.2 crore

NewsGoogle News·4 Oct · 4d ago

(opens in new tab)

12 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·29 Sept · 1w ago

Sun Pharmaceutical has entered into a licensing agreement for lerodalcibep, a novel drug candidate, expanding its specialty portfolio.

BSE · Company Update·28 Sept · 1w ago

(opens in new tab)

Sun Pharma to acquire Innovcare Lifesciences for ₹271.2 crore

NewsGoogle News·20 Sept · 3w ago

(opens in new tab)
Neutral / worth noting (4)

Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October

NewsLivemint·7 Oct · today

(opens in new tab)

Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's Ratings (Baa1, Stable Outlook) and S&P Global Ratings (BBB+, Stable Outlook). These ratings are inves

BSE · Company Update·8 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (4)

Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amount

NewsCnbc-Tv18·11 Sept · 4w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from HSBC Securities

Every call and its outcome